We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Medications for Alcohol Use Disorders

Fabio Caputo, MD, PhD1; Marco Domenicali, MD, PhD2; Mauro Bernardi, MD2
[+] Author Affiliations
1Department of Internal Medicine, SS Annunziata Hospital, Cento, Italy
2“G. Fontana” Centre for Treatment of Alcohol Addiction, University of Bologna, Bologna, Italy
JAMA. 2014;312(13):1350-1351. doi:10.1001/jama.2014.10158.
Text Size: A A A
Published online


To the Editor A systematic review and meta-analysis1 highlighted the current pharmacotherapy for outpatients affected by alcohol use disorders. However, regarding off-label drugs, some issues need more discussion, particularly those regarding nalmefene use.

Nalmefene is no longer an off-label drug in Europe. Nalmefene was approved in February 2013 by the European Medicines Agency and was granted market authorization in the European Union for the reduction of alcohol consumption in alcohol-dependent patients with a high drinking risk level (defined as >60 g/d for men and >40 g/d for women).2 As cited by Jonas and colleagues, 2 randomized, double-blind, placebo-controlled trials have been published in which patients with alcohol use disorders received nalmefene as needed (ie, in self-identified risk situations, when drinking is imminent, or as soon as possible after drinking) for 6 months. However, a post hoc analysis of these studies only including patients with at least a high drinking risk level both at screening and randomization showed more interesting results: nalmefene reduced the number of heavy drinking days (treatment difference: −3.2 days; P < .001) and total alcohol consumption (treatment difference: −14.3 g/d; P < .001) at month 6 significantly more than placebo.3


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




October 1, 2014
Daniel E. Jonas, MD, MPH; Cynthia Feltner, MD, MPH; James C. Garbutt, MD
1Department of Medicine, University of North Carolina, Chapel Hill
2Department of Psychiatry, University of North Carolina, Chapel Hill
JAMA. 2014;312(13):1351-1352. doi:10.1001/jama.2014.10170.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...